48-Weeks Results of the RESIST Trials
48-Weeks Results of the RESIST Trials
Pilar García-Gasco
NULL
*Correspondence: Pilar García-Gasco, Email not available
Abstract
The one year results of the RESIST trials were reportedat the last Retrovirus Conference, held in Denverin February, 2006. Tipranavir is a non-peptidicprotease inhibitor (PI) recently approved in severalcountries for the treatment of HIV infection. The drughas been designed to be active against PI-resistantviruses. RESIST trials 1 and 2 are prospective, multicenterstudies in which heavily antiretroviral-experiencedpatients were randomized to be rescued withTPV/r or a comparative PI (CPI/r), in all cases with anoptimized backbone of other antiretroviral drugs.
